WO2012177856A3 - Cognition modification - Google Patents

Cognition modification Download PDF

Info

Publication number
WO2012177856A3
WO2012177856A3 PCT/US2012/043520 US2012043520W WO2012177856A3 WO 2012177856 A3 WO2012177856 A3 WO 2012177856A3 US 2012043520 W US2012043520 W US 2012043520W WO 2012177856 A3 WO2012177856 A3 WO 2012177856A3
Authority
WO
WIPO (PCT)
Prior art keywords
cognition
subject
modification
cognitive impairment
methods
Prior art date
Application number
PCT/US2012/043520
Other languages
French (fr)
Other versions
WO2012177856A2 (en
Inventor
Stephen H. Curry
George P. Hess
Brad GOULDTHORPE
Original Assignee
Adispell, Inc.
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adispell, Inc., Cornell University filed Critical Adispell, Inc.
Publication of WO2012177856A2 publication Critical patent/WO2012177856A2/en
Publication of WO2012177856A3 publication Critical patent/WO2012177856A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Abstract

The present invention relates to methods of improving cognition and treating or preventing cognitive impairment in a subject. These methods involve administering to a subject in need of cognitive improvement or to a subject having or at risk for developing impaired cognition a ligand which binds to the nicotinic acetylcholine receptor and improves cognition or treats or prevents cognitive impairment in the subject.
PCT/US2012/043520 2011-06-21 2012-06-21 Cognition modification WO2012177856A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499577P 2011-06-21 2011-06-21
US61/499,577 2011-06-21

Publications (2)

Publication Number Publication Date
WO2012177856A2 WO2012177856A2 (en) 2012-12-27
WO2012177856A3 true WO2012177856A3 (en) 2013-02-21

Family

ID=47423200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/043520 WO2012177856A2 (en) 2011-06-21 2012-06-21 Cognition modification

Country Status (1)

Country Link
WO (1) WO2012177856A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023664A2 (en) * 2013-08-12 2015-02-19 Adispell, Inc. Therapeutic treatment for drug poisoning and addiction
JOP20190282A1 (en) 2017-06-09 2019-12-05 Novartis Ag Compounds and compositions for inducing chondrogenesis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227385A (en) * 1992-03-13 1993-07-13 Wake Forest University Method for treatment of neurodegenerative diseases
US6683090B1 (en) * 1999-11-18 2004-01-27 Astrazeneca Ab N-azabicyclo-amide derivatives
US20100069468A1 (en) * 2006-07-12 2010-03-18 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
US20110124631A1 (en) * 2009-05-11 2011-05-26 Gerhard Koenig Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227385A (en) * 1992-03-13 1993-07-13 Wake Forest University Method for treatment of neurodegenerative diseases
US6683090B1 (en) * 1999-11-18 2004-01-27 Astrazeneca Ab N-azabicyclo-amide derivatives
US20100069468A1 (en) * 2006-07-12 2010-03-18 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
US20110124631A1 (en) * 2009-05-11 2011-05-26 Gerhard Koenig Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors

Also Published As

Publication number Publication date
WO2012177856A2 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
NZ730763A (en) Methods of treating a tauopathy
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2012173846A3 (en) Peptidomimetic macrocycles
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2013102042A3 (en) Dual variable domain immunoglobulins against il-13 and/or il-17
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
IN2012DN02521A (en)
WO2014106001A3 (en) Dual specific binding proteins having a receptor sequence
MX2013006875A (en) Anti-notch1 antibodies.
IL222198A (en) Humanized anti cxcr4 antibodies for the treatment of cancer
WO2012040727A3 (en) Methods for diagnosis and treatment of neurodegenerative diseases or disorders
WO2013177035A3 (en) Humaneered anti-factor b antibody
MX2012012901A (en) Methods for the treatment of il-1î² related conditions.
WO2011130347A3 (en) Methods for enhancing axonal regeneration
WO2013135602A3 (en) Combination therapy for the treatment of ovarian cancer
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
EP2938633A4 (en) Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2013090633A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
WO2011008947A3 (en) Treatment and diagnosis of immune disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12802519

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12802519

Country of ref document: EP

Kind code of ref document: A2